Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy

Neslisah Seyrek1,2 · Eva Hollemans1 · Eleni-Rosalina Andrinopoulou3,4 · Susanne Osanto5 · Rob C. M. Pelger6 · Henk G. van der Poel7 · Elise Bekers8 · Sebastiaan Remmers9 · Ivo G. Schoots2 · Geert J. L. H. van Leenders1

Received: 30 December 2021 / Revised: 7 February 2022 / Accepted: 8 February 2022
© The Author(s) 2022

Abstract
Percentage Gleason pattern 4, invasive cribriform and/or intraductal carcinoma (IC/IDC) and minor pattern 5 are recognized as independent parameters for prostate cancer outcome, but are not incorporated in current grade groups (GGs). Two proof-of-principle studies have proposed alternative grading schemes based on percentage Gleason pattern 4/5 (integrated quantitative Gleason score; IQ-Gleason) and IC/IDC presence (cribriform grade; cGrade). Our objective was to compare the performance of GG, IQ-Gleason and cGrade for predicting biochemical recurrence and metastasis after radical prostatectomy (RP). RP specimens of 1064 patients were pathologically reviewed and graded according to the three schemes. Discriminative power for prediction of biochemical recurrence-free (BCRFS) and metastasis-free (MFS) survival was compared using Harrell’s c-index. The GG distribution at RP was 207 (19.4%) GG1, 472 (44.4%) GG2, 126 (11.8%) GG3, 140 (13.2%) GG4 and 119 (11.2%) GG5. Grading according to 5-tier IQ-Gleason and cGrade systems led to categorical shifts in 49.8% and 29.7% of cases, respectively. Continuous IQ-Gleason had the best performance for predicting BCRFS (c-index 0.743, 95% confidence interval (CI) 0.715–0.771), followed by cGrade (c-index 0.738, 95% CI 0.712–0.759), 5-tier categorical IQ-Gleason (c-index 0.732, 95% CI 0.695–0.750) and GG (c-index 0.718, 95% CI 0.691–0.744). Continuous IQ-Gleason (c-index 0.834, 95% CI 0.802–0.863) and cGrade (c-index 0.834, 95% CI 0.808–0.866) both had better predictive value for MFS than categorical IQ-Gleason (c-index 0.823, 95% CI 0.788–0.857) and GG (c-index 0.806, 95% CI 0.777–0.839). In conclusion, the performance of prostate cancer grading can be improved by alternative grading schemes incorporating percent Gleason pattern 4/5 and IC/IDC.

Keywords Prostate cancer · Radical prostatectomy · Gleason score · Grade group · Cribriform · Percent
Introduction

The Gleason grading system is the cornerstone of risk assessment and prediction of clinical outcome in prostate cancer (PCa) patients. In radical prostatectomy (RP) specimens, the Gleason score (GS) is determined by adding the two most frequent growth patterns resulting in a final score of 2 to 10. Based on the work of Pierorazio et al. and Epstein et al., the GS is categorized into five grade groups (GGs) [6, 13]. The International Society of Urological Pathology (ISUP), World Health Organization (WHO) and Genitourinary Pathology Society (GUPS) endorse reporting of GGs in conjunction with GS [4, 5, 9]. The advantages of the GG system are its simplicity, explicit distinction of GS 3 + 4 and 4 + 3 and categorization of GS ≤ 6 as GG1.

In recent years, the clinical relevance of pathological parameters such as Gleason pattern 4 quantity, presence of invasive cribriform and intraductal (IDC) carcinoma, and minor/tertiary Gleason patterns has been well acknowledged [1–3, 7, 8, 12, 15]. For instance, the risk of postoperative biochemical recurrence is increasing with incremental Gleason 4 pattern quantity and presence of minor Gleason pattern 5 [1, 2, 10, 15]. Furthermore, invasive cribriform and/or intraductal carcinoma (IC/IDC) has been associated with biochemical recurrence, metastatic disease and disease-specific survival [3, 7, 8, 12]. Consequently, the ISUP and GUPS both recommend including these specific features in pathology reports [4, 19].

Although of prognostic significance, it is unclear how percent pattern 4, IC/IDC and minor pattern 5 altogether translate to individual risk assessment and should be used in clinical practice. For instance, it is unknown whether patients with GG2 with 20% Gleason pattern 4, IDC and tertiary pattern 5 have worse outcome than those with GG3 with 60% pattern 4 but no cribriform carcinoma or tertiary pattern 5. Few groups have demonstrated that alternative grading schemes incorporating some of these pathological factors had significantly better discriminative value than current GGs [14, 17, 18]. On biopsy and RP specimens, Sauter et al. found that an integrated quantitative Gleason (IQ-Gleason) score, which is purely based on Gleason pattern 4 and 5 quantities, led to better risk stratification for biochemical recurrence-free survival (BCRFS) [14]. Alternatively, modification of the GG system for the presence of IC/IDC on biopsies — labelled as cribriform grade (cGrade) — resulted in improved discriminative value for disease-specific and metastasis-free survival (MFS) [18].

Although these proof-of-principle studies reveal that optimization of the current GG system is possible, no studies have independently validated the prognostic value of these models. The objective of the current study was to compare the discriminative ability of GG, IQ-Gleason and cGrade for BCRFS and MFS in a RP cohort.

Materials and methods

Patient selection

Patients who had undergone RP for prostatic adenocarcinoma at three medical centres in The Netherlands between 2000 and 2017 were included in this study: 854 patients were operated at Erasmus MC, University Medical Centre, Rotterdam; 96 at Leiden University Medical Centre (LUMC), Leiden; and 137 at Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute (NKI), Amsterdam. While the RP specimens of Erasmus MC were unselected consecutive samples, those from LUMC and NKI were selected for having GG3–5 disease in their original pathology report to increase the number of high-grade tumours. Patients who had undergone hormonal, radiation and/or viral therapy (n = 23) before RP were excluded. RP specimens were fixed in neutral-buffered formalin, after which they were sectioned transversely and embedded entirely for diagnostic purposes. All slides were available for pathology review. The institutional Medical Research Ethics Committee approved this study (MEC-2018–1614).

Pathological evaluation

All 1064 RP specimens were reviewed in joint sessions by two investigators (EH, GvL), blinded to clinical outcome. In case of discordan dices, the assessment of the senior genito-urinary pathologist (GvL) was included in the study database. For each specimen, the following features were recorded: GS and GG according to the 2014 ISUP/2016 WHO guidelines, pT stage according to the American Joint Committee on Cancer (AJCC) TNM 8th edition, surgical margin status, presence of IC/IDC and percent Gleason 4 and 5 growth patterns. Invasive cribriform and IDC were not distinguished and grouped for all analyses. In case of multifocality, we only monitored the characteristics of the index tumour defined as the tumour with the highest grade, stage or volume. Tertiary patterns occupying < 5% of the tumour volume and IDC were not included in the GG. The GG concordance rate at revision was 88/135 (65.2%) for RP from NKI and 39/94 (41.5%) for specimens from LUMC; this discordance rate was affected by the fact that the original tumour grading had been performed by a large number of general pathologists and that several samples were originally graded before the 2005 ISUP consensus meeting.
Clinical follow-up

Clinical follow-up after RP consisted of 6 monthly and later annual monitoring of serum prostate-specific antigen (PSA) levels. Biochemical recurrence was defined as PSA levels ≥ 0.2 ng/ml measured at two consecutive points in time, at least 3 months apart with undetectable PSA levels after RP. Post-operative lymph node and distant metastases were confirmed by biopsy, imaging or multidisciplinary consensus.

IQ-Gleason and cGrade assessment

The IQ-Gleason score is calculated by summing Gleason pattern 4 and 5 percentages. Ten points are added if any Gleason pattern 5 is present and 7.5 points extra if it exceeds 20%. This results in a continuous IQ-Gleason score from 0 to 117.5 points. For comparison purposes, we a priori categorized IQ-Gleason into five ordinal groups as follows: 0–25, 26–50, 51–75, 76–100 and 101–117.5.

cGrade is based on the GG system, where the grade is decreased by 1 point in case no invasive cribriform and intraductal carcinoma is present in GG2–5 tumours. In the rare case of GG1 with IDC, 1 point is added leading to cGrade2 classification. Schematic descriptions and examples of IQ-Gleason and cGrade are depicted in Fig. 1.

Statistical analysis

Missing PSA values (n = 27) were imputed using the median PSA value. BCRFS and MFS were analysed using the Cox proportional hazards model and visualized by Kaplan–Meier curves. Hazard ratios (HR) for survival time were calculated using univariate Cox proportional hazard regression. For all models, Cox proportional hazard assumptions were confirmed by log-log survival plots, and Schoenfeld residuals were plotted as a function of time, at least 3 months apart with undetectable PSA levels (PSA) levels. Biochemical recurrence was defined as PSA value was ≥ 0.2 ng/ml measured at two consecutive points in time, at least 3 months apart with undetectable PSA levels after RP. Post-operative lymph node and distant metastases were confirmed by biopsy, imaging or multidisciplinary consensus.

Results were considered significant when the two-sided p value was < 0.05.

Results

Patient characteristics

The median age of the 1064 patients who had undergone RP was 64.6 years (interquartile range (IQR) 60.2–68.1), and the serum PSA level was 8.3 ng/ml (IQR 6.0–13.2). The GG distribution was as follows: 207 (19.4%) GG1, 472 (44.4%) GG2, 126 (11.8%) GG3, 140 (13.2%) GG4 and 119 (11.2%) GG5. The pathological tumour stage was pT2 in 582 (54.7%), pT3a in 334 (31.4%), pT3b in 145 (13.6%) and pT4 in 3 (0.3%) patients. Positive surgical margins were observed in 390 (36.7%) patients. Out of 665 (62.5%) patients who had undergone pelvic lymph node dissection, 63 (5.9%) had lymph node metastasis. IC/IDC was present in 568 (53.4%) patients, and 118 (11.1%) had tertiary (<5%) Gleason pattern 5. The median clinical follow-up for men without events was 54.1 (IQR 12.2–95.2) months. Biochemical recurrence occurred in 342 (32.1%) patients after 36.3 months (IQR 9.3–78.5), and 136 (12.8%) men developed distant metastasis after 58.5 months (IQR 18.6–100.1 months). The clinical and pathological characteristics stratified per GG are shown in Table 1.

IQ-Gleason and cGrade

The distribution of the IQ-Gleason categories was 497 (46.7%) IQ-Gleason1, 203 (19.1%) IQ-Gleason2, 117 (11.0%) IQ-Gleason3, 163 (15.3%) IQ-Gleason4 and 84 (7.9%) IQ-Gleason5. GG and IQ-Gleason categories were similar in 545 (51.2%) men (Table 2a). The most prominent difference was the categorization of 287 (60.8%) GG2 patients as IQ-Gleason1, which can be attributed to patients with <25% Gleason pattern 4. Only 50/140 (35.7%) of GG4 patients were classified as IQ-Gleason4, which was mostly due to categorization of 71/76 (93.4%) GS 3 + 5 = 8 tumours in lower groups, while 62/126 (49.2%) GG3 tumours were upgraded and 57/119 (47.9%) GG5 downgraded.

The cGrade distribution was 417 (39.2%) cGrade1, 270 (25.4%) cGrade2, 170 (16.0%) cGrade3, 105 (9.9%) cGrade4 and 102 (9.6%) cGrade5. In total, 759 (71.3%) men had similar GG and cGrade category (Table 2b). Incorporation of IC/IDC in cGrade had the most impact on GG2 patients, of whom 219 (46.4%) were categorized as cGrade1. Furthermore, 52/140 (37.1%) GG4 tumours were classified as cGrade3. cGrade and IQ-Gleason category were concordant in 633 (59.5%) men with considerable redistribution among all groups (Table 2c).

Biochemical recurrence-free survival

Post-operative biochemical recurrence occurred in 16 (7.7%) GG1, 107 (22.7%) GG2, 74 (58.7%) GG3, 68 (48.6%) GG4 and 77 (64.7%) GG5 tumours. For categorized IQ-Gleason, recurrence rates were 76/497 (15.3%), 50/203 (24.6%), 59/117 (50.4%), 98/163 (60.1%) and 59/84 (70.2%), respectively, and for cGrade 48/417 (11.5%), 77/270 (28.5%), 88/170 (51.8%), 54/105 (51.4%) and 75/102 (73.5%). BCRFS of the three grading models is shown in Table 3 and Fig. 2a. The cGrade model (c-index 0.738, 95% confidence interval (CI) 0.712–0.759) had higher discriminative
power than conventional GGs (c-index 0.718, 95% CI 0.691–0.744). IQ-Gleason analysed as a continuous variable (c-index 0.743, 95% CI 0.715–0.771) had the highest discriminative ability for BCRFS, although this decreased considerably after its categorization (c-index 0.723, 95% CI 0.695–0.750) (Fig. 3a).

**Metastasis-free survival**

Post-operative distant metastases were observed in none of GG1, 18 (3.8%) GG2, 35 (27.8%) GG3, 36 (25.7%) GG4 and 47 (39.5%) GG5 tumours. According to 5-tier IQ-Gleason, 4/497 (0.8%), 17/203 (8.4%), 27/117 (23.1%), 51/163 (31.1%) and 37/84 (44.0%) patients experienced distant metastasis, respectively. For cGrade, metastatic events were found in 0/417 (0%) cGrade1, 19/270 (7.0%) cGrade2, 38/170 (22.4%) cGrade3, 32/73 (30.5%) cGrade4 and 47/102 (46.1%) cGrade5 patients. MFS is presented in Table 4 and Fig. 2b. Due to the absence of events in GG1 and cGrade1 tumours, for each grading system, the 1st and 2nd groups were clustered to enable statistical analysis. The continuous IQ-Gleason (c-index 0.834, 95% CI 0.802–0.863) and cGrade (c-index 0.834, 95% CI 0.808–0.866) both had comparable and highest discriminative value for MFS. The discriminative power of categorized IQ-Gleason (c-index 0.823, 95% CI 0.788–0.857) was also higher than that of conventional GG (c-index 0.806, 95% CI 0.777–0.839) (Fig. 3b).
Discussion

Gleason pattern 4 percentage, presence of IC/IDC and minor/tertiary Gleason patterns have been well acknowledged as independent prognostic features of prostate cancer. Therefore, according to the latest ISUP and GUPS recommendations, these pathological factors should be included in pathology reports in conjunction with the GS and GG [4, 5]. Albeit of clinical significance, it is yet unclear how to combine this pathological information into

### Table 1

Clinicopathological characteristics of patients undergoing RP (n = 1064) for prostate cancer

|                      | GG1 n = 207 | GG2 n = 472 | GG3 n = 126 | GG4 n = 140 | GG5 n = 119 |
|----------------------|-------------|-------------|-------------|-------------|-------------|
| Age (IQR)            | 63.2 (59.8–66.7) | 64.6 (59.9–68.0) | 66.2 (60.9–69.9) | 65.3 (61.4–68.5) | 64.7 (60.8–70.0) |
| PSA (IQR)            | 6.3 (4.0–9.2) | 8.3 (6.0–12.9) | 11.6 (7.2–19.2) | 10.0 (7.2–68.5) | 11.3 (7.1–19.0) |
| pT                   |             |             |             |             |             |
| T2                   | 185 (89.4%) | 268 (56.8%) | 37 (29.4%) | 67 (47.9%) | 25 (21.0%) |
| T3a                  | 20 (9.7%) | 169 (35.8%) | 53 (42.1%) | 44 (31.4%) | 48 (40.3%) |
| T3b                  | 2 (1.0%) | 35 (7.4%) | 36 (28.6%) | 28 (20.0%) | 44 (37.0%) |
| T4                   | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.7%) | 2 (1.7%) |
| Positive surgical margins | 35 (16.9%) | 156 (33.1%) | 64 (50.8%) | 67 (47.9%) | 68 (57.1%) |
| Pelvic lymph node dissection | 134 (64.7%) | 262 (55.5%) | 87 (69.0%) | 91 (65.0%) | 91 (76.5%) |
| Metastasis on pelvic lymph node dissection | 0 (0.0%) | 13 (2.8%) | 21 (16.7%) | 12 (8.6%) | 17 (14.3%) |
| Tertiary Gleason 5 pattern | 0 (0.0%) | 56 (11.9%) | 53 (42.1%) | 9 (6.4%) | 0 (0.0%) |
| Invasive cribriform and/or intraductal carcinoma | 9 (4.3%)* | 252 (53.4%) | 118 (93.7%) | 87 (62.1%) | 102 (85.7%) |
| Biochemical recurrence | 16 (7.7%) | 107 (22.7%) | 74 (58.7%) | 68 (48.6%) | 77 (64.7%) |
| Distant metastasis | 0 (0.0%) | 18 (3.8%) | 35 (27.8%) | 36 (25.7%) | 47 (39.5%) |

*Nine cases represent IDC

### Table 2

Distribution of grade groups (GGs), categorical integrated quantitative Gleason (IQ-Gleason) score and cribriform grade (cGrade)

|                      | IQ-Gleason1 | IQ-Gleason2 | IQ-Gleason3 | IQ-Gleason4 | IQ-Gleason5 | Total |
|----------------------|-------------|-------------|-------------|-------------|-------------|-------|
| GG1                  | 207         | -           | -           | -           | -           | 207   |
| GG2                  | 287         | 163         | 22          | -           | -           | 472   |
| GG3                  | -           | 1           | 63          | 59          | 3           | 126   |
| GG4                  | 3           | 39          | 29          | 50          | 19          | 140   |
| GG5                  | -           | -           | 3           | 54          | 62          | 119   |
| Total                | 497         | 203         | 117         | 163         | 84          | 1064  |

|                      | cGrade1     | cGrade2     | cGrade3     | cGrade4     | cGrade5     | Total |
|----------------------|-------------|-------------|-------------|-------------|-------------|-------|
| GG1                  | 198         | 9           | -           | -           | -           | 207   |
| GG2                  | 219         | 253         | -           | -           | -           | 472   |
| GG3                  | -           | 8           | 118         | -           | -           | 126   |
| GG4                  | -           | -           | 52          | 88          | -           | 140   |
| GG5                  | -           | -           | -           | 17          | 102         | 119   |
| Total                | 417         | 270         | 170         | 105         | 102         | 1064  |

|                      | IQ-Gleason1 | IQ-Gleason2 | IQ-Gleason3 | IQ-Gleason4 | IQ-Gleason5 | Total |
|----------------------|-------------|-------------|-------------|-------------|-------------|-------|
| cGrade1              | 356         | 56          | 5           | -           | -           | 417   |
| cGrade2              | 138         | 107         | 21          | 4           | -           | 270   |
| cGrade3              | 1           | 25          | 71          | 68          | 5           | 170   |
| cGrade4              | 2           | 15          | 18          | 45          | 25          | 105   |
| cGrade5              | -           | -           | 2           | 46          | 54          | 102   |
| Total                | 497         | 203         | 117         | 163         | 84          | 1064  |
comprehensive risk stratification models for individual patients. Recently, two proof-of-principle studies have shown that the discriminative value of conventional GGs can significantly be improved by incorporating novel pathological characteristics in alternative grading systems [14, 18]. In this study, we show that continuous IQ-Gleason and cGrade both outperformed GGs particularly in prediction of MFS and to a lesser extent of BCRFS. These findings demonstrate that prostate cancer grading can significantly be improved by incorporating Gleason pattern 4 percentage, tertiary patterns and IC/IDC in new grading schemes.

This is the first study to independently validate IQ-Gleason for prediction of BCRFS after RP [14]. Furthermore, we show that the additive value of IQ-Gleason is even stronger for predicting MFS, which to our knowledge has not been reported yet. For comparison purposes, we also analysed IQ-Gleason as a 5-tier system, which outperformed GG for MFS but not for BCRFS, indicating that categorization led to significant loss of discriminative power. Finally, we confirm the findings of our previous biopsy study showing that cGrade has better discriminative ability for predicting MFS [18]. Both alternative grading systems led to considerable reclassification of original GGs, with only 51% of IQ-Gleason and 71% of cGrade categories being similar to the respective GG. For both alternative grading systems, the most prominent effect was the re-categorization of many GG2 patients with low-risk features as IQ-Gleason1 or cGrade1.

| Group | Grade group | IQ-Gleason | cGrade |
|-------|-------------|------------|--------|
| 1     | ref         | ref        | ref    |
| 2     | 4.1 (2.4–7.0) | 2.0 (1.4–2.8) | 3.6 (2.5–5.2) |
| 3     | 14.4 (8.3–24.9) | 4.8 (3.4–6.8) | 7.2 (5.1–10.3) |
| 4     | 10.2 (5.9–17.6) | 6.5 (4.8–8.8) | 6.9 (4.6–10.1) |
| 5     | 18.0 (10.4–31.0) | 8.5 (6.0–12.0) | 14.5 (9.5–19.9) |

All p-values are < 0.001
CI confidence interval, HR hazard ratio, ref reference

Table 3 Cox proportional hazard models for biochemical recurrence-free survival stratified by grade group (GG), categorical integrated quantified Gleason (IQ-Gleason) score and cribriform grade (cGrade)

![Fig. 2 a](image)

**Fig. 2 a** Biochemical recurrence-free and **b** metastasis-free survival (log-rank) stratified by grade group (GG), categorical integrated quantitative Gleason (IQ-Gleason) and cribriform grade (cGrade)
respectively, doubling the number of men in the lowest risk category. While these men remained at very low risk of less than 1% for developing post-operative metastasis, BCR rates in IQ-Gleason1 and cGrade1 were higher than in GG1.

The GS/GG has been the global standard for prostate cancer grading for many years. Disadvantages of the current grading system are that it is prone to inter-observer variability and does not implement the new prognostic factors. The better discriminative value of cGrade is mostly related to the classification of the large group of GG2 men without IC/IDC as cGrade1. As cGrade is based on the GG system, it will still suffer from considerable inter-observer variability. At the same time, the IQ-Gleason assessment is time consuming and might result in delays in daily clinical practice. Yet, apart from its better performance, a strong point of continuous IQ-Gleason is that it is less susceptible to inter-observer variability related to the assessment of minor high-grade components. For instance, a RP with 70% GP3, 27% GP4 and 3% GP5 is graded as GG2 with tertiary pattern 5 according to ISUP, GUPS and WHO recommendations; however,
Table 4 Cox proportional hazard models for metastasis-free survival stratified by grade group (GG), categorical integrated quantified Gleason (IQ-Gleason) score and cribriform grade (cGrade)

| Group | Grade Group | IQ-Gleason | cGrade |
|-------|-------------|------------|--------|
|       | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| 1 & 2 | ref | ref | ref |
| 3     | 12.7 (7.2–22.4) | 9.1 (5.2–16.2) | 9.9 (5.7–17.2) |
| 4     | 11.5 (6.5–20.4) | 13.5 (8.1–22.6) | 13.3 (7.5–23.6) |
| 5     | 22.5 (13.0–39.0) | 22.8 (13.2–39.1) | 26.3 (15.3–45.2) |

Groups 1 and 2 added together to avert eternity. All p-values are <0.001

CI confidence interval, HR hazard ratio, ref reference

have impact on patient communication and follow-up in the large group of IQ-Gleason1 and cGrade1 men.

The strong points of this study were the detailed monitoring of Gleason pattern percentages and growth patterns. The retrospective design, short median follow-up period of 54 months and relatively small sample size were restrictions, limiting the power of the statistical analyses. Furthermore, the current RP cohort was specifically enriched for high-grade tumours from other centres to increase statistical power in high-grade patients, which might have introduced a bias.

In conclusion, this is the first study validating the clinical performance of two alternative prostate cancer grading systems. We show that both IQ-Gleason and cGrade outperformed GGs in having better discriminative ability for MFS and BCRFS. This study shows that improvement of current prostate cancer grading is possible and could result in comprehensive incorporation of new prognostic pathological parameters in clinical practice.

Author contribution N. Seyrek and E. Hollemans performed the research. N. Seyrek analysed the data and wrote the manuscript. S. Osanto, R.C.M. Pelger, H.G. van der Poel and E. Bekers included patients with clinical follow-up. E.R. Andrinopoulou and S. Remmers supervised statistical analysis and result presentation. I.G. Schoots and G.J.L.H. van Leenders supervised the analysis and manuscript drafting. G.J.L.H. van Leenders designed the study.

Funding This study was sponsored by a generous grant of the Jaap Schouten Foundation.

The manuscript contains original unpublished work and is not being submitted for publication elsewhere. All authors agree with the results presented as well as the final draft of the manuscript. The institutional Medical Research Ethics Committee approved this study (MEC-2018–1614).

Declarations

Ethical approval The manuscript contains original unpublished work and is not being submitted for publication elsewhere. All authors agree with the results presented as well as the final draft of the manuscript. The institutional Medical Research Ethics Committee approved this study (MEC-2018–1614).

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Springer
References

1. Baras AS, Nelson JB, Han M, Parwani AV, Epstein JI (2017) The effect of lenticular (cystic) Gleason pattern 5 on the new prostate cancer grade groups. Hum Pathol 63:27–32. https://doi.org/10.1016/j.humpath.2016.12.008

2. Choy B, Pearce SM, Anderson BB, Shallhav AL, Zagaja G, Egg-ener SE, Paner GP (2016) Prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy. Am J Surg Pathol 40:1400–1406. https://doi.org/10.1097/PAS.0000000000000691

3. Downes MR, Xu B, van der Kwast TH (2019) Gleason grade pat-terns in nodal metastasis and corresponding prostatectomy speci-mens: impact on patient outcome. Histopathology 75:715–722. https://doi.org/10.1111/his.13938

4. Epstein JI, Amin MB, Fine SW, Alagaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Goredskiy JB, Guo CC, Hansei DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong Q, Kryvenko ON, Kunju LP, Lal P, Latorum M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani AV, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakos MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Trpkov K (2020) The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med. https://doi.org/10.5858/arpha.2020-00155-RA

5. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphreys PA, Grading C (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244–252. https://doi.org/10.1097/PAS.0000000000000530

6. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciarki JP, Nyberg T, Klein EA (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69:428–435. https://doi.org/10.1016/j.eururo.2015.06.046

7. Flood TA, Schieda N, Sim J, Breau RH, Morash C, Belanger EC, Robertson SJ (2018) Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade 5 prostate cancer. Virchows Arch 472:205–212. https://doi.org/10.1007/s00428-017-2241-9

8. Harding-Jackson N, Kryvenko ON, Whittington EE, Eastwood DC, Tjionas GA, Jorda M, Iczkowski KA (2016) Outcome of Gleason 3 + 5 = 8 prostate cancer diagnosed on needle biopsy: prognostic comparison with Gleason 4 + 4 = 8. J Urol 196:1076–1081. https://doi.org/10.1016/j.juro.2016.05.105

9. Humphrey PA, Moeh H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours. Eur Urol 70:106–119. https://doi.org/10.1016/j.eururo.2016.02.028

10. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kaminoha O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotot M, Tsuzuki T (2019) Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients. Mod Pathol 32:122–127. https://doi.org/10.1016/j.modpa.2019.04.024

11. Kweldam CF, Kummerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ (2017) Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. Mod Pathol 30:1126–1132. https://doi.org/10.1038/modpathol.2017.29

12. Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ (2015) Cribiform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28:457–464. https://doi.org/10.1038/modpathol.2014.116

13. Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason Grade Grouping: data based on the modified Gleason Scoring System. BJU Int 111:753–760. https://doi.org/10.1111/j.1464-410X.2012.11611.x

14. Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Kreh T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsoulrakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzz E, Michl U, Budäus L, Nikoli D, Theheran I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawabab AAA, Uhlig R, Huland H, Heinzer H, Graeven M, Schlommod T (2018) Integrating tertiary Gleason 5 patterns into quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol 73:674–683. https://doi.org/10.1016/j.eururo.2017.01.015

15. Sauter G, Steurer S, Clauditz TS, Krach T, Wittmer C, Lutz F, Lennartz M, Janssen T, Hakimi N, Simon R, von Petersdorff-Campenh H, Jacobsen F, von Loga K, Wilczak W, Minner S, Tsoulrakis MC, Chirico V, Haese A, Heinzer H, Beyer B, Graeven M, Michl U, Salomon G, Steuber T, Budäus L, Göbel C, Malsy-Mink J, Kutzera S, Fraune C, Göbel C, Huland H, Schlommod T (2016) Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol 69:592–598. https://doi.org/10.1016/j.eururo.2015.10.029

16. Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Beker E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG, van Leenders G (2021) Cribiform architecture outperforms percent Gleason pattern 4 and tertiary pattern 5 in predicting outcome of Grade Group 2 prostate cancer patients. Histopathology. https://doi.org/10.1111/his.14590

17. Taguchi S, Uemura Y, Fujimura T, Morikawa T, Naito A, Kawai T, Suzuki M, Kume H, Fukuhara H (2020) Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model. BMC Cancer 20:371. https://doi.org/10.1186/s12888-020-06880-8

18. van Leenders G, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoeof EL, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ (2020) Improved prostate cancer biopsy grading by incorporation of invasive cribiform and intraductal carcinoma in the 4 grade groups. Eur Urol 77:191–198. https://doi.org/10.1016/j.eururo.2019.07.051

19. van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litijens G, McKenney JK, Melamed J, Mottet N, Paner GP, Samartunga H, Schoots IG, Simko JP, Tsuzuki T, Varma M, Warren AJ, Wheeler TM, Williamson SR, Iczkowski KA (2020) The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol 44:e285-e99. https://doi.org/10.1097/PAS.0000000000001497

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.